Clinical Trial Update: Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety, efficacy, pharmacokinetics, and pharmacodynamics of ALXN1820 in adults with sickle cell disease; the study was termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• ALXN1820

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Sickle Cell Disease (SCD) | Phase 2 | Status: TERMINATED | Results posted: 2025-01-13